Strategic view: FDA-UniQure Tussle and Pfizer's Obesity Drug Approval in China
Strategic implications in focus: China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more crowded.
Editorial Staff
1 min read
Updated 4 months ago
FDA and UniQure are in a dispute over regulatory matters.
Pfizer's obesity drug has received approval in China.
The obesity treatment market is expected to grow significantly.